4 Analysts Have This to Say About NeoGenomics
Portfolio Pulse from Benzinga Insights
In the last quarter, NeoGenomics (NASDAQ:NEO) received 2 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts. The company's average 12-month price target is $18.75, which has increased by 2.29% over the past month.
August 21, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeoGenomics received mostly positive ratings from analysts, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, the majority of the ratings for NeoGenomics are positive, which could lead to increased investor confidence and a potential rise in the stock price. The increase in the average 12-month price target over the past month also indicates a positive outlook for the stock.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100